Keith W Crawford

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211)
    Keith W Crawford
    Department of Clinical Pharmacology, Johns Hopkins University, Baltimore, MD 21287, USA
    J Acquir Immune Defic Syndr 53:598-605. 2010
  2. ncbi Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir
    Keith W Crawford
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    AIDS Res Hum Retroviruses 26:635-43. 2010
  3. ncbi Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement
    Keith W Crawford
    Johns Hopkins University, School of Medicine, Division of Clinical Pharmacology, Baltimore, MD, USA
    Lancet Infect Dis 12:550-60. 2012

Detail Information

Publications3

  1. ncbi Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211)
    Keith W Crawford
    Department of Clinical Pharmacology, Johns Hopkins University, Baltimore, MD 21287, USA
    J Acquir Immune Defic Syndr 53:598-605. 2010
    ..This substudy of AIDS Clinical Trials Group (ACTG) Protocol 5211 explored the relationship between antiretroviral effect and plasma concentrations of vicriviroc, an investigational CCR5 antagonist for HIV infection...
  2. ncbi Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir
    Keith W Crawford
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    AIDS Res Hum Retroviruses 26:635-43. 2010
    ..Age-related changes in the pharmacokinetics of antiretroviral drugs may be of increasing importance as the HIV-infected population ages and as older individuals comprise an increasing proportion of new diagnoses...
  3. ncbi Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement
    Keith W Crawford
    Johns Hopkins University, School of Medicine, Division of Clinical Pharmacology, Baltimore, MD, USA
    Lancet Infect Dis 12:550-60. 2012
    ..Optimising pharmacoenhancement and extending shelf life are additional strategies. The conference highlighted a range of interventions; optimum cost savings could be achieved through combining approaches...